// App-Quantinova.ai

BSH19‐PO‐136 : Tociluzimab for the Management of Recurrent Resistant Post Transfusion Hyperhaemolysis in Sickle Cell Disease

Researchers

Presenter

  • L. Linpower

Principal Investigators

  • S. Silvapalaratnam

  • H. Wisbey

  • S. Jain

  • A. Agapidou

  • N. Win

  • D.A. Tsitsikas

Medical Centers

  • Haemoglobinopathy Service, Department of Haematology

  • Intensive Care Unit, Homerton University Hospital NHS Foundationn Trust

  • Tooting Centre, National Health Service Blood and Transplant, Tooting, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Acute chest syndrome

  • Sickle cell anemia

Biomarkers

  • Ferritin

  • Lactate dehydrogenase

  • Stearoyl-CoA desaturase

  • Red Blood Cells

Drug/Treatment

  • Tocilizumab

  • Allopurinol

  • IVIG

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved